BMS’ big merger bet is still on with latest CAR-T filingBristol-Myers Squibb and development partner bluebird bio have filed their multiple myeloma CAR-T with the FDA, the final Share XBMS’ big merger bet is still on with latest CAR-T filinghttps://pharmaphorum.com/news/bms-and-bluebird-file-multiple-myeloma-car-t/
LentiGlobin gene therapy for sickle cell on course for filing, says bluebirdIt has been an amazing year for patients with sickle cell disease (SCD) with two new drug approvals Share XLentiGlobin gene therapy for sickle cell on course for filing, says bluebirdhttps://pharmaphorum.com/news/lentiglobin-gene-therapy-for-sickle-cell-on-course-for-filing-says-bluebird/
FDA approves Global Blood Therapeutics’ sickle cell pillGlobal Blood Therapeutics has seen its sickle cell disease drug approved by the FDA, promising to be the Share XFDA approves Global Blood Therapeutics’ sickle cell pillhttps://pharmaphorum.com/news/fda-approves-global-blood-therapeutics-sickle-cell-pill/
CAR-TCR Summit EuropeEngineering A Cancer-Free World Share XCAR-TCR Summit Europehttps://pharmaphorum.com/events/car-tcr-summit-europe/
Novo Nordisk builds in haemophilia with Bluebird Bio gene editing dealAnxious not to be left behind in the haemophilia market, Novo Nordisk has forged an alliance with Bluebird Share XNovo Nordisk builds in haemophilia with Bluebird Bio gene editing dealhttps://pharmaphorum.com/news/novo-nordisk-builds-in-haemophilia-with-bluebird-bio-gene-editing-deal/
bluebird presents long-term data from CALD gene therapybluebird bio has produced updated data from its gene therapy for the rare genetic neurological disease cerebral adrenoleukodystrophy Share Xbluebird presents long-term data from CALD gene therapyhttps://pharmaphorum.com/news/bluebird-presents-long-term-data-from-cald-gene-therapy/
bluebird offers instalment payments for Zynteglo gene therapybluebird bio is pricing its thalassaemia gene therapy Zynteglo at €1.57 million ($1.8 million) in Europe, but with Share Xbluebird offers instalment payments for Zynteglo gene therapyhttps://pharmaphorum.com/news/bluebird-offers-instalment-payments-for-zynteglo-gene-therapy/
Bringing gene therapies to marketDoug Danison, vice-president, head of access, value and evidence strategy at bluebird bio, a gene therapy company, looks Share XBringing gene therapies to markethttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/bluebird-bio-gene-therapies-market/
bluebird claims first approval for gene therapy Zynteglo in EUbluebird bio has its first ever product approval, getting a green light from the EMA for Zynteglo, its Share Xbluebird claims first approval for gene therapy Zynteglo in EUhttps://pharmaphorum.com/news/bluebird-claims-first-approval-for-gene-therapy-zynteglo-in-eu/
